Combination Therapy of F16IL2 and Doxorubicin in Solid Tumour Patients

NCT01131364 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

29

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumor
Breast Cancer

Interventions

DRUG: F16IL2 in combination with doxorubicin

Sponsor

Philogen S.p.A.